Regenxbio Financials
Regenxbio (RGNX) reported $170.4M in revenue for fiscal year 2025, up 104.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue rebounds, but the operating model still depends on external funding because research spending and cash burn outrun commercial scale.
FY2025 sales rebounded to$170M and free cash burn narrowed to-$126M , but that did not make the business self-funding because R&D still ran above revenue. The clearer shift is on the balance sheet: financing replaced internally generated cash as debt-to-equity moved to 3.4x from 0.8x in FY2024.
Capex was only
Even with stronger sales, operating margin remained
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Regenxbio's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Regenxbio scores -2.49, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($793.5M) relative to total liabilities ($350.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Regenxbio passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Regenxbio reported a net loss of $193.9M while operations used $124.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Regenxbio reported an operating loss of $161.2M against $45.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Regenxbio generated $170.4M in revenue in fiscal year 2025. This represents an increase of 104.5% from the prior year.
Regenxbio's EBITDA was -$145.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 33.0% from the prior year.
Regenxbio reported -$193.9M in net income in fiscal year 2025. This represents an increase of 14.6% from the prior year.
Regenxbio earned -$3.76 per diluted share (EPS) in fiscal year 2025. This represents an increase of 18.1% from the prior year.
Cash & Balance Sheet
Regenxbio recorded an outflow of $126.4M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 28.0% from the prior year.
Regenxbio held $34.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Regenxbio's operating margin was -94.6% in fiscal year 2025, reflecting core business profitability. No change is given against fiscal year 2024: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Regenxbio's ROE was -188.7% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 101.3 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Regenxbio invested $228.3M in research and development in fiscal year 2025. This represents an increase of 9.5% from the prior year.
Regenxbio invested $2.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 0.9% from the prior year.
Not reported for fiscal year 2025.
RGNX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $174.5M | $170.4M+104.5% | $83.3M-7.7% | $90.2M-19.9% | $112.7M-76.0% | $470.3M+204.3% | $154.6M+338.7% | $35.2M-83.9% | $218.5M+2002.4% | $10.4M+126.5% | $4.6M-39.5% | $7.6M+24.0% | $6.1M+0.5% | $6.1M |
| Cost of Revenue | N/A | N/A | $33.6M-9.8% | $37.2M-31.8% | $54.5M+5.2% | $51.8M+45.1% | $35.7M+333.4% | $8.2M-14.5% | $9.6M+464.1% | $1.7M+1643.9% | $98K0.0% | $98K-19.7% | $122K-29.5% | $173K |
| Gross Profit | N/A | N/A | $49.8M-6.2% | $53.0M-8.9% | $58.2M-86.1% | $418.5M+252.1% | $118.9M+340.3% | $27.0M-87.1% | $208.9M+2305.2% | $8.7M+93.4% | $4.5M-40.0% | $7.5M+24.9% | $6.0M+1.4% | $5.9M |
| R&D Expenses | $229.1M | $228.3M+9.5% | $208.5M-10.2% | $232.3M-4.2% | $242.5M+33.6% | $181.4M+9.1% | $166.3M+33.9% | $124.2M+48.1% | $83.9M+46.6% | $57.2M+25.8% | $45.5M+163.2% | $17.3M+248.3% | $5.0M-1.8% | $5.1M |
| SG&A Expenses | $85.6M | $82.9M+8.1% | $76.6M-13.4% | $88.5M+3.8% | $85.3M+7.5% | $79.3M+24.3% | $63.8M+23.2% | $51.8M+40.6% | $36.9M+35.3% | $27.2M+15.4% | $23.6M+98.0% | $11.9M+209.3% | $3.9M-29.6% | $5.5M |
| Operating Income | -$164.1M | -$161.2M+30.9% | -$233.3M+13.0% | -$268.1M-2.0% | -$262.9M-264.3% | $160.0M+234.2% | -$119.2M+20.0% | -$149.0M-269.1% | $88.1M+216.1% | -$75.9M-16.1% | -$65.3M-182.4% | -$23.1M-528.4% | -$3.7M+22.9% | -$4.8M |
| Interest Expense | $41.9M | $45.0M+255.5% | $12.7M+84.5% | $6.9M-70.5% | $23.3M-11.5% | $26.3M+3308.2% | $771K | N/A | N/A | N/A | N/A | $20K-93.8% | $321K-47.5% | $611K |
| Income Tax | N/A | $0 | $0+100.0% | -$152K-81.0% | -$84K-100.6% | $13.4M+155.9% | $5.2M+290.2% | -$2.8M-165.9% | $4.2M | $0+100.0% | -$435K | $0 | $0 | $0 |
| Net Income | -$196.4M | -$193.9M+14.6% | -$227.1M+13.8% | -$263.5M+6.0% | -$280.3M-319.3% | $127.8M+214.9% | -$111.3M-17.4% | -$94.7M-194.8% | $99.9M+236.6% | -$73.2M-16.2% | -$63.0M-176.0% | -$22.8M-469.8% | -$4.0M+25.7% | -$5.4M |
| EPS (Diluted) | — | -$3.76+18.1% | -$4.59+23.8% | -$6.02+7.4% | -$6.50-323.4% | $2.91+197.7% | -$2.98-15.5% | -$2.58-194.5% | $2.73+211.4% | -$2.45-2.9% | -$2.38 | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RGNX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $453.0M-2.8% | $466.0M-18.8% | $574.0M-31.1% | $833.3M-25.2% | $1.1B+57.3% | $708.2M+42.2% | $497.9M-8.4% | $543.8M+173.7% | $198.7M+15.0% | $172.7M-22.0% | $221.4M+6241.4% | $3.5M | N/A |
| Current Assets | $281.3M+1.2% | $278.0M-17.0% | $335.0M-19.5% | $416.0M-19.8% | $518.8M-2.3% | $531.2M+54.0% | $345.0M+2.1% | $337.9M+101.1% | $168.0M+79.9% | $93.4M-21.0% | $118.1M+3798.0% | $3.0M | N/A |
| Cash & Equivalents | $34.5M-40.1% | $57.5M+66.6% | $34.5M-64.4% | $97.0M-71.9% | $345.2M+2.0% | $338.4M+386.8% | $69.5M-8.0% | $75.6M+62.0% | $46.7M+87.8% | $24.8M-54.1% | $54.1M+4727.5% | $1.1M+0.2% | $1.1M |
| Accounts Receivable | $26.4M+28.8% | $20.5M-17.4% | $24.8M-11.7% | $28.1M-13.4% | $32.4M-24.6% | $43.0M+12.7% | $38.1M+20.7% | $31.6M+440.2% | $5.8M | N/A | $2.1M+165.3% | $805K | N/A |
| Total Liabilities | $350.3M+69.8% | $206.3M-21.3% | $262.2M-17.3% | $317.1M-9.3% | $349.6M+5.8% | $330.4M+592.5% | $47.7M+36.4% | $35.0M+123.5% | $15.6M+42.3% | $11.0M+140.5% | $4.6M-79.0% | $21.8M | N/A |
| Current Liabilities | $118.1M+14.4% | $103.2M-20.8% | $130.3M-0.1% | $130.4M0.0% | $130.5M+60.2% | $81.4M+141.9% | $33.7M+51.9% | $22.2M+53.6% | $14.4M+49.3% | $9.7M+122.8% | $4.3M-52.8% | $9.2M | N/A |
| Total Equity | $102.7M-60.4% | $259.7M-16.7% | $311.7M-39.6% | $516.2M-32.5% | $764.3M+102.3% | $377.8M-16.1% | $450.2M-11.5% | $508.8M+178.0% | $183.0M+13.2% | $161.7M-25.4% | $216.8M+1285.3% | -$18.3M-31.4% | -$13.9M |
| Retained Earnings | -$1.1B-20.8% | -$932.1M-32.2% | -$705.0M-59.7% | -$441.6M-173.9% | -$161.2M+44.2% | -$289.1M-62.6% | -$177.8M-114.2% | -$83.0M+55.8% | -$187.8M-63.9% | -$114.6M-122.0% | -$51.6M-79.2% | -$28.8M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
RGNX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$246.7M | -$124.0M+28.4% | -$173.1M+20.7% | -$218.4M-5.3% | -$207.5M-194.8% | $218.9M+504.9% | -$54.1M+49.8% | -$107.7M-202.9% | $104.6M+280.5% | -$58.0M-19.4% | -$48.6M-115.7% | -$22.5M-838.5% | -$2.4M+20.4% | -$3.0M |
| Capital Expenditures | $3.0M | $2.4M-0.9% | $2.4M-75.5% | $10.0M-67.6% | $30.7M-63.5% | $84.2M+213.3% | $26.9M+129.3% | $11.7M-11.7% | $13.3M+85.4% | $7.2M-12.1% | $8.1M+1461.1% | $522K | N/A | N/A |
| Free Cash Flow | -$249.7M | -$126.4M+28.0% | -$175.6M+23.1% | -$228.4M+4.1% | -$238.2M-276.8% | $134.7M+266.4% | -$80.9M+32.2% | -$119.4M-230.7% | $91.4M+240.2% | -$65.2M-14.9% | -$56.7M-146.2% | -$23.0M | N/A | N/A |
| Investing Cash Flow | $216.3M | -$15.9M-115.3% | $103.4M-45.8% | $190.9M+1700.7% | -$11.9M+97.1% | -$406.6M-431.3% | $122.8M+31.2% | $93.6M+133.5% | -$279.4M-5732.1% | -$4.8M-124.7% | $19.4M | N/A | N/A | N/A |
| Financing Cash Flow | -$12.7M | $116.8M+26.0% | $92.7M+365.1% | -$35.0M-21.2% | -$28.8M-114.8% | $195.3M-2.5% | $200.2M+2290.3% | $8.4M-95.9% | $204.4M+141.7% | $84.6M+70990.8% | $119K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
RGNX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | 59.7%+1.0pp | 58.8%+7.2pp | 51.6%-37.4pp | 89.0%+12.1pp | 76.9%+0.3pp | 76.6%-19.0pp | 95.6%+12.0pp | 83.6%-14.3pp | 97.9%-0.8pp | 98.7%+0.7pp | 98.0%+0.8pp | 97.2% |
| Operating Margin | -94.6% | -280.0% | -297.1% | -233.2% | 34.0%+111.1pp | -77.1% | -422.9% | 40.3% | -730.1% | -1423.8% | -304.9% | -60.2%+18.3pp | -78.5% |
| Net Margin | -113.8% | -272.5% | -292.0% | -248.7% | 27.2%+99.2pp | -72.0% | -268.9% | 45.7% | -704.0% | -1372.1% | -300.6% | -65.4%+23.1pp | -88.5% |
| Return on Equity | -188.7%-101.3pp | -87.5%-2.9pp | -84.5%-30.2pp | -54.3%-71.0pp | 16.7%+46.2pp | -29.4%-8.4pp | -21.0%-40.7pp | 19.6%+59.6pp | -40.0%-1.1pp | -38.9%-28.4pp | -10.5% | N/A | N/A |
| Return on Assets | -42.8%+5.9pp | -48.7%-2.8pp | -45.9%-12.3pp | -33.6%-45.1pp | 11.5%+27.2pp | -15.7%+3.3pp | -19.0%-37.4pp | 18.4%+55.2pp | -36.8%-0.4pp | -36.4%-26.2pp | -10.3%+104.4pp | -114.7% | N/A |
| Current Ratio | 2.38-0.3x | 2.69+0.1x | 2.57-0.6x | 3.19-0.8x | 3.98-2.5x | 6.52-3.7x | 10.25-5.0x | 15.24+3.6x | 11.64+2.0x | 9.66-17.6x | 27.23+26.9x | 0.33 | N/A |
| Debt-to-Equity | 3.41+2.6x | 0.790.0x | 0.84+0.2x | 0.61+0.2x | 0.46-0.4x | 0.87+0.8x | 0.110.0x | 0.070.0x | 0.090.0x | 0.070.0x | 0.02 | N/A | N/A |
| FCF Margin | -74.2% | -210.7% | -253.1% | -211.3% | 28.6%+81.0pp | -52.4% | -339.0% | 41.8% | -626.9% | -1235.7% | -303.6% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Regenxbio Ranks
Frequently Asked Questions
What is Regenxbio's annual revenue?
Regenxbio (RGNX) reported $170.4M in total revenue for fiscal year 2025. This represents a 104.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Regenxbio's revenue growing?
Regenxbio (RGNX) revenue grew by 104.5% year-over-year, from $83.3M to $170.4M in fiscal year 2025.
Is Regenxbio profitable?
No, Regenxbio (RGNX) reported a net income of -$193.9M in fiscal year 2025.
What is Regenxbio's EBITDA?
Regenxbio (RGNX) had EBITDA of -$145.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Regenxbio's operating margin?
Regenxbio (RGNX) had an operating margin of -94.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Regenxbio's return on equity (ROE)?
Regenxbio (RGNX) has a return on equity of -188.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Regenxbio's free cash flow?
Regenxbio (RGNX) recorded an outflow of $126.4M in free cash flow during fiscal year 2025. This represents a 28.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Regenxbio's operating cash flow?
Regenxbio (RGNX) recorded an outflow of $124.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Regenxbio's total assets?
Regenxbio (RGNX) had $453.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Regenxbio's capital expenditures?
Regenxbio (RGNX) invested $2.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Regenxbio spend on research and development?
Regenxbio (RGNX) invested $228.3M in research and development during fiscal year 2025.
What is Regenxbio's current ratio?
Regenxbio (RGNX) had a current ratio of 2.38 as of fiscal year 2025, which is generally considered healthy.
What is Regenxbio's debt-to-equity ratio?
Regenxbio (RGNX) had a debt-to-equity ratio of 3.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regenxbio's return on assets (ROA)?
Regenxbio (RGNX) had a return on assets of -42.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regenxbio's cash runway?
Based on fiscal year 2025 data, Regenxbio (RGNX) had $34.5M in cash against an annual operating cash burn of $124.0M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Regenxbio's Altman Z-Score?
Regenxbio (RGNX) has an Altman Z-Score of -2.49, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Regenxbio's Piotroski F-Score?
Regenxbio (RGNX) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Regenxbio's earnings high quality?
Regenxbio (RGNX) reported a net loss of $193.9M while operations used $124.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regenxbio cover its interest payments?
Regenxbio (RGNX) reported an operating loss of $161.2M against $45.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Regenxbio?
Regenxbio (RGNX) scores 55 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.